Join to View Full Profile
200 Medical Plaza# 365CLos Angeles, CA 90095
Phone+1 310-206-7663
Fax+1 310-206-1609
Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Otto Yang, based in Los Angeles, CA, is an Infectious Disease specialist affiliated with UCLA Medical Center-Santa Monica and Ronald Reagan UCLA Medical Center. He completed his fellowship in Infectious Disease at Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical School, and his residency in Internal Medicine at NYU Grossman School of Medicine. Dr. Yang has significant experience in flow cytometry, virology, molecular biology, emerging infectious diseases, and cellular immunology. His recent publications include works in journals such as the Journal of Acquired Immune Deficiency Syndromes, Vaccine, and Scientific Reports. He is also involved in clinical trials, including studies on COVID-19 and HIV. Dr. Yang has been recognized with the CMS Meaningful Use Stage 1 Certification by Epic Systems Corporation.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1993 - 1997
NYU Grossman School of MedicineResidency, Internal Medicine, 1990 - 1993
The Warren Alpert Medical School of Brown UniversityClass of 1990
Certifications & Licensure
CA State Medical License 2000 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Specimen Repository for HIV Immunopathogenesis Start of enrollment: 2017 Jul 31
- Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Start of enrollment: 2020 Apr 17
- Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection Start of enrollment: 2017 May 01
- Join now to see all
Publications & Presentations
PubMed
- SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.Michael Y Shino, F Javier Ibarrondo, Otto O Yang
Vaccine. 2025-03-19 - Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): a Randomized, Double-Blind, Placebo-Controlled Trial.Joseph C Gathe, Edwin Dejesus, Moti N Ramgopal, Charlotte-Paige Rolle, Otto O Yang
Journal of Acquired Immune Deficiency Syndromes. 2025-02-20 - Response to the Letter to the Editor on Laboratory Monitoring After Lentiviral Vector Exposure.Gary R Fujimoto, Dawn P Wooley, Karen B Byers, Otto O Yang, Amy J Behrman
Journal of Occupational and Environmental Medicine. 2025-01-23
Journal Articles
- Cross-Reactivity Against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte ClonesOtto Yang, MD, mBio
- Highly Attenuated Infection with a Vpr-Deleted Molecular Clone of HIV-1Peter A Anton, Jennifer A Fulcher, Otto O Yang, Joel N Blankson, The Journal of Infectious Diseases
Press Mentions
Vaccines and Long COVID: What Do We Know?October 4th, 2024- Here’s What to Know About the COVID-19 Summer SurgeAugust 30th, 2024
- Right Here's What to Know Concerning the COVID-19 Summer Time SurgeAugust 30th, 2024
- Join now to see all
Grant Support
- Harnessing the Pathogenesis of CMV Against HIVUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Harnessing the Pathogenesis of CMV Against HIVUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Harnessing the Pathogenesis of CMV Against HIVUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2029
- Addressing Evolving Infectious ThreatsUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
- Addressing Evolving Infectious ThreatsUNIVERSITY OF CALIFORNIA LOS ANGELES2023–2028
- In vivo CAR-T-cell HIV therapy using in vitro reconstituted virus-like particlesUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2026
- In vivo CAR-T-cell HIV therapy using in vitro reconstituted virus-like particlesUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2026
- Mucosal B-cell aging in PLWHUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2025
- Mucosal B-cell aging in PLWHUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2025
- Therapeutic Anti-HIV Chimeric Antigen Receptors Via Stem Cell DeliveryUNIVERSITY OF CALIFORNIA LOS ANGELES2020–2024
- Translational AIDS And Viral Pathogenesis Training (51)National Institute Of Allergy And Infectious Diseases2010–2012
- HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1999–2012
- Identifying And Closing GAPS In TCR Coverage Of HIV-1 EscapeNational Institute Of Allergy And Infectious Diseases2011
- Addressing Intra-/Inter-Clade Diversity In HIV Vaccine Design By Immune FocusingNational Institute Of Allergy And Infectious Diseases2010–2011
- Immune Pressure On HIV-1 Nef By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2002–2011
- Mucosal And Peripheral NK-T Cells In HIV InfectionNational Institute Of Allergy And Infectious Diseases2006–2007
- HIV-1 Excape From Inhibiton By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases2003–2007
- HIV-1 Escape From Inhibition By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1998–1999
- Inhibition Of HIV 1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1996–1998
- Inhibition Of HIV-1 By Cytotoxic T LymphocytesNational Institute Of Allergy And Infectious Diseases1995–1996
Research History
- ProfessorUCLA Medical School1999 - Present
- InstructorMassachusetts General Hospital, Harvard Medical School1997 - 1999
Other Languages
- Taiwanese
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
